Advanced search×

Nanotechnology in vaccine delivery

Laura J Peek, C Russell Middaugh, and Cory Berkland

Adv Drug Deliv Rev 60(8):14 (2008) PMID 18325628

With very few adjuvants currently being used in marketed human vaccines, a critical need exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral, cellular and mucosal immunity. Such crucial vaccine components could facilitate the development of novel vaccines for viral and parasitic infections, such as hepatitis, HIV, malaria, cancer, etc. In this review, we discuss clinical trial results for various vaccine adjuvants and delivery vehicles being developed that are approximately nanoscale (<1000 nm) in size. Humoral immune responses have been observed for most adjuvants and delivery platforms while only viral vectors, ISCOMs and Montanide(TM) ISA 51 and 720 have shown cytotoxic T cell responses in the clinic. MF59 and MPL(R) have elicited Th1 responses, and virus-like particles, non-degradable nanoparticles and liposomes have also generated cellular immunity. Such vaccine components have also been evaluated for alternative routes of administration with clinical successes reported for intranasal delivery of viral vectors and proteosomes and oral delivery of a VLP vaccine.

Copyright © 2008 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.addr.2007.05.017
Version: za2963e q8za4 q8zb5 q8zc4 q8zdf q8ze7 q8zfc q8zg0

Similar articles you may find interesting…

  1. Editorial Board
    Author(s) unavailable

    Adv Drug Deliv Rev 61(9):ii (2009)

  2. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
    Sarbari S Acharya and Sanjeeb K SK Sahoo

    Adv Drug Deliv Rev 63(3):14 (2011) PMID 20965219

    As mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumor tissues by circumventing all the shortcomings of conventional chemotherapy. During the past decade, the importance...
  3. Targeted delivery of nanoparticles for the treatment of lung diseases
    Shirzad Azarmi, Wilson H Roa, and Raimar Löbenberg

    Adv Drug Deliv Rev 60(8):13 (2008) PMID 18308418

    Targeted delivery of drug molecules to organs or special sites is one of the most challenging research areas in pharmaceutical sciences. By developing colloidal delivery systems such as liposomes, micelles and nanoparticles a new frontier was opened for improving drug delivery. Nanoparticles with th...